Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278040 | 1.00 | ABL1 (0.35) | ABL1GRM5SYKCHEK2KMT2A | |
| SCHEMBL1277643 | 0.91 | LMNA (0.37) | ABL1 | |
| SCHEMBL1277639 | 0.91 | LMNA (0.37) | ABL1 | |
| SCHEMBL1277817 | 0.86 | SYK (0.34) | ABL1GRM5SYKKMT2A | |
| SCHEMBL1277814 | 0.86 | SYK (0.34) | ABL1GRM5SYKKMT2A | |
| SCHEMBL1278149 | 0.85 | GABRA1 (0.32) | — | |
| SCHEMBL1278145 | 0.85 | GABRA1 (0.32) | — | |
| SCHEMBL13769210 | 0.84 | LMNA (0.30) | — | |
| SCHEMBL1277417 | 0.84 | SYK (0.33) | ABL1GRM5SYKKMT2A | |
| SCHEMBL1277415 | 0.84 | SYK (0.33) | ABL1GRM5SYKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309586-B2 | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | LG LIFE SCIENCES LTD. (KR) | 2012-11-13 | — | — | US | disclosed |
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG CHEM, LTD. (KR) | 2012-04-12 | — | — | US | disclosed |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2010-10-21 | — | — | US | disclosed |
| EP-2220081-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009082152-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCKR, GCK, GALK1 | ABL1 3217/4885GRM5 1972/4885SYK 808/4885 |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCK, GCKR, HK1 | ABL1 3927/4885GRM5 1999/4885SYK 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.